Current Status of Computer-Aided Drug Design for Type 2 Diabetes
暂无分享,去创建一个
[1] D. Barford,et al. Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B. , 2000, Molecular cell.
[2] Matthew P. Repasky,et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.
[3] A. Saxena,et al. Identification of novel PTP1B inhibitors by pharmacophore based virtual screening, scaffold hopping and docking. , 2014, European journal of medicinal chemistry.
[4] Thierry Langer,et al. Efficient overlay of small organic molecules using 3D pharmacophores , 2007, J. Comput. Aided Mol. Des..
[6] I. Kuntz,et al. DOCK 6: combining techniques to model RNA-small molecule complexes. , 2009, RNA.
[7] Gerard J Kleywegt,et al. Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. , 2003, Angewandte Chemie.
[8] Omprakash Tanwar,et al. Structure based virtual screening of MDPI database: discovery of structurally diverse and novel DPP-IV inhibitors. , 2014, Bioorganic & medicinal chemistry letters.
[9] Santosh A. Khedkar,et al. Successful applications of computer aided drug discovery: moving drugs from concept to the clinic. , 2010, Current topics in medicinal chemistry.
[10] Allen B Reitz,et al. Linear interaction energy models for beta-secretase (BACE) inhibitors: Role of van der Waals, electrostatic, and continuum-solvation terms. , 2006, Journal of molecular graphics & modelling.
[11] Markus Christen,et al. The GROMOS software for biomolecular simulation: GROMOS05 , 2005, J. Comput. Chem..
[12] M. Taha,et al. Ligand-based modeling followed by in vitro bioassay yielded new potent glucokinase activators. , 2015, Journal of molecular graphics & modelling.
[13] D. Popov. Novel protein tyrosine phosphatase 1B inhibitors: interaction requirements for improved intracellular efficacy in type 2 diabetes mellitus and obesity control. , 2011, Biochemical and biophysical research communications.
[14] J. A. Grant,et al. Gaussian docking functions. , 2003, Biopolymers.
[15] Manuela Pavan,et al. DRAGON SOFTWARE: AN EASY APPROACH TO MOLECULAR DESCRIPTOR CALCULATIONS , 2006 .
[16] Thierry Langer,et al. LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..
[17] Charles C. Persinger,et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.
[18] D. E. Clark. What has computer-aided molecular design ever done for drug discovery? , 2006, Expert opinion on drug discovery.
[19] G. Klebe,et al. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.
[20] René Thomsen,et al. MolDock: a new technique for high-accuracy molecular docking. , 2006, Journal of medicinal chemistry.
[21] Thomas Lengauer,et al. Evaluation of the FLEXX incremental construction algorithm for protein–ligand docking , 1999, Proteins.
[22] I D Kuntz,et al. Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D. , 1997, Chemistry & biology.
[23] P. Sanseau,et al. Computational Drug Repositioning: From Data to Therapeutics , 2013, Clinical pharmacology and therapeutics.
[24] H. Kubinyi. Comparative Molecular Field Analysis (CoMFA) , 2002 .
[25] Richard D. Taylor,et al. Improved protein–ligand docking using GOLD , 2003, Proteins.
[26] D. Vanderwall,et al. Inhibitors of dihydrodipicolinate reductase, a key enzyme of the diaminopimelate pathway of Mycobacterium tuberculosis. , 2001, Biochimica et biophysica acta.
[27] R. Cramer,et al. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.
[28] Thierry Langer,et al. Molecule-pharmacophore superpositioning and pattern matching in computational drug design. , 2008, Drug discovery today.
[29] J. Bajorath,et al. Quo vadis, virtual screening? A comprehensive survey of prospective applications. , 2010, Journal of medicinal chemistry.
[30] Holger Gohlke,et al. The Amber biomolecular simulation programs , 2005, J. Comput. Chem..
[31] David E. Shaw,et al. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results , 2006, J. Comput. Aided Mol. Des..
[32] B. Shoichet,et al. Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. , 2002, Journal of medicinal chemistry.
[33] P. Sasikumar,et al. Antidiabetic effect of Merremia emarginata Burm. F. in streptozotocin induced diabetic rats. , 2012, Asian Pacific journal of tropical biomedicine.
[34] R. Friesner,et al. Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.
[35] Silja Weber,et al. Aminomethylpyrimidines as novel DPP-IV inhibitors: a 10(5)-fold activity increase by optimization of aromatic substituents. , 2004, Bioorganic & medicinal chemistry letters.
[36] Martin Stahl,et al. Novel dihydrofolate reductase inhibitors. Structure-based versus diversity-based library design and high-throughput synthesis and screening. , 2003, Journal of medicinal chemistry.
[37] Hege S. Beard,et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.
[38] D. Porte,et al. Glucokinase activators (GKAs) promise a new pharmacotherapy for diabetics , 2010, F1000 medicine reports.
[39] Florian Nigsch,et al. Computational toxicology: an overview of the sources of data and of modelling methods. , 2009, Expert opinion on drug metabolism & toxicology.
[40] E. Bradley,et al. Performance of 3D-database molecular docking studies into homology models. , 2004, Journal of medicinal chemistry.
[41] M. Karplus,et al. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .
[42] N. de Kimpe,et al. Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. , 2004, Journal of ethnopharmacology.
[43] C. Bailey,et al. Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes. , 2006, Expert opinion on emerging drugs.
[44] David S. Goodsell,et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..
[45] M. Taha,et al. Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening. , 2007, Journal of molecular graphics & modelling.
[46] A. Combs. Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer. , 2010, Journal of medicinal chemistry.